KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therapeutically targetable driver pathways of this disease. While epidermal growth fac...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Breast Cancer Res
Päätekijät: Roberts, Melyssa S., Anstine, Lindsey J., Finke, Viviane S., Bryson, Benjamin L., Webb, Bryan M., Weber-Bonk, Kristen L., Seachrist, Darcie D., Majmudar, Parth R., Keri, Ruth A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7301986/
https://ncbi.nlm.nih.gov/pubmed/32552913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01305-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia